Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Increase in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 27,645 shares, a growth of 172,681.2% from the August 15th total of 16 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 474,592 shares, the short-interest ratio is currently 0.1 days.

Oncotelic Therapeutics Trading Down 1.0%

Shares of OTLC stock opened at $0.03 on Friday. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The firm’s 50-day simple moving average is $0.04 and its 200-day simple moving average is $0.04. The firm has a market cap of $13.69 million, a P/E ratio of 0.05 and a beta of -0.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.08 and a quick ratio of 0.08.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.